About this information
Search the summaries of completed Access to Information (ATI) requests to find information about ATI requests made to the Government of Canada after January 2020. If you find a summary of interest, you can request a copy of the records at no cost using the form below each summary. Requests made through this form are considered informal requests and are not subject to the same requirements as requests under the Access to Information Act (ATIA). For additional information, please see the “About Access to Information Requests” webpage.
If you don’t find what you are looking for you can request additional government records under an institution’s control by contacting the institution’s Access to Information and Privacy Coordinator or by submitting a formal access to information request.
*All information provided will incorporate the necessary exemptions and exclusions as per the Access to Information Act and the Privacy Act.
Download datasets of the summaries of completed access to information requests.
Current Search
Report Type
Organization
Disposition
Year
Month
Found 440 record(s)
Req # A-2022-000454
Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate. Identify the Canadian Reference Product, as described in section C.08.002.1 of the Food and Drug Regulations, to which the new drug in the Desmopressin ANDS is compared.Organization: Health Canada
July 2023
Req # A-2022-000689
Requests for the following submissions: INTELENCE -ETRAVIRINE, JANSSEN INC. Notice of Compliance (NOC) Date: 2/2/2022. Supplement to a New Drug Submission (SNDS). All meeting minutes. Reviewer notes. Pre-submission meeting packages.Organization: Health Canada
July 2023
Req # A-2022-000853
The initial cover letter indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22 for the medicinal ingredient amphotericin B. The Screening Acceptance Letter from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for amphotericin B which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2022-06-22.Organization: Health Canada
July 2023
Req # A-2022-000930
The 42 responses to the Notice of Intent to restrict the marketing and advertising of opioids found at this link. https://www.canada.ca/en/health-canada/services/opioids/responding-canada-opioid-crisis/advertising-opioid-medications/what-we-heard.htmlOrganization: Health Canada
July 2023
Req # A-2022-001058
All records between Health Canada and the Canadian Food Inspection Agency (CFIA) between January 1, 2021 and September 28, 2022, in relation to instituting a ban on the entry of commercial dogs.Organization: Health Canada
July 2023
Req # A-2022-001060
All records between Health Canada and the Canadian Food Inspection Agency (CFIA) between January 1, 2015 and July 30, 2021, in relation to instituting a ban on the entry of commercial dogs.Organization: Health Canada
July 2023
Req # A-2022-001398
Attestations to Health Canada regarding the risks of alteration to craniofacial structure, narrowing of the upper airway, compromised respiratory function, and the risk of obstructive sleep apnea posed by use of the Orthodontic Facebow/Headgear, also known as the Cervical Headgear, specifically the Item 6 attestation of compliance with Section 10 and 11(1) of the Canada Medical Device Regulations (SOR/98-282). Any attestations of the risks of these appliances under Section 10 of the Regulations. This request refers to all of the following licences for this Class II medical device: Licence No.: 34554, Licence No.: 69095, Licence No.: 78248, Licence No.: 15841, Licence No.: 87779, Licence No.: 30093, Licence No.: 99152, Licence No.: 39363, Licence No.: 107355, Licence No. 31323, and Licence No.: 95578.Organization: Health Canada
July 2023
Req # A-2022-001492
The initial cover letters indicating the brand name of the reference drug product and the dosage form of the generic drug in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24 for the medicinal ingredient tiotopium bromide monohydrate. The Screening Acceptance Letters from Health Canada to the generic drug manufacturer confirming completion of screening of the Abbreviated New Drug Submission (ANDS) for tiotropium bromide monohydrate which appears in Health Canada’s list of “Generic Drug Submissions Under Review” dated 2023-02-24.Organization: Health Canada
July 2023
Req # A-2022-001593
Request for a closed advertising complaint regarding KayMediSpa and its use of a product Biosun Pdo Threads. The complaint was received by Health Canada on Nov. 10, 2020. It was about the direct-to-consumer advertising of unauthorized claims. The complaint received by Health Canada. The compliance letter sent to request correction of non-compliance. List of materials that have been modified/removed/discontinued by KayMediSpa in response to the complaint.Organization: Health Canada
July 2023
Req # A-2022-001650
Health Canada is currently reviewing an Abbreviated New Drug Submission (ANDS) seeking approval of a product containing the medicinal ingredient desmopressin acetate which was accepted into review on or after December 1, 2022. Advise of the dosage form in which the drug in this ANDS is proposed to be sold, as described in paragraph C.08.002(2)(l) of the Food and Drug Regulations.Organization: Health Canada
July 2023